HuMax IL8

Drug Profile

HuMax IL8

Alternative Names: HuMax-IL8; HuMax-Inflam; MDX 018

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Genmab; Medarex
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 01 Nov 2016 Bristol-Myers Squibb completes a phase-I clinical trial in Solid tumours in USA (IV) (NCT02536469)
  • 05 Jul 2016 Cormorant Pharmaceuticals has been acquired and merged into Bristol-Myers Squibb
  • 01 Aug 2015 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02536469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top